You are here

SBIR Phase I: Catechol Linker Oligosaccharide Combinations for Antimicrobial Surfaces

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 2143961
Agency Tracking Number: 2143961
Amount: $255,862.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: BT
Solicitation Number: NSF 21-562
Timeline
Solicitation Year: 2021
Award Year: 2023
Award Start Date (Proposal Award Date): 2023-05-15
Award End Date (Contract End Date): 2024-04-30
Small Business Information
100 Jersey Ave Ste. A360
New Brunswick, NJ 08902
United States
DUNS: N/A
HUBZone Owned: Yes
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Randell Clevenger
 (908) 917-3631
 randyc@mosutech.com
Business Contact
 Randell Clevenger
Phone: (908) 917-3631
Email: randyc@mosutech.com
Research Institution
N/A
Abstract

The broader/commercial impact of this Small Business Innovation Research (SBIR) Phase 1 project is a decrease in the devastating effects of deep implant-related infections.The technology could result in advances to the clinical health and welfare of the American public by improving clinical outcomes and decreasing morbidity and mortality. The technology addressed by this project may protect surgical implants, such as joint replacements and spinal fusion systems from bacterial colonization and developing infections. This technology could significantly reduce the greater than $3 billion cost to the US healthcare system from implant related infections. This antimicrobial technology could be used beyond medical applications for such things as food packaging to decrease foodborne diseases and more than double shelf-life of certain food products. Additionally, the linker technology developed through this project may be used to create super slick or self-cleaning surfaces with applications in the aerospace and marine industries resulting in increased fuel efficiency and performance._x000D_
_x000D_
The project aims to develop a homogeneous, covalently bound, linker molecule attached to medical implant material (titanium alloy) upon which a quaternary ammonium-modified oligosaccharide will be subsequently attached. Oligosaccharides are known to be biocompatible and quaternized oligosaccharides are highly potent antimicrobials. A treated medical implant could possess a powerfully antimicrobial surface so that, during surgery, any bacteria that encounter the surface will be killed. In this way, it is hoped that the avascular surface of the implant will not serve as a site for biofilm formation and growth and thus, reduce the incidence of perioperative infections. The key to any successful surface modification is the quality of the chemical attachment of linkers and active molecules to that surface. Polyphenols and catechols such as dopamine are ideal candidates for investigation as these molecules are generally known for their facility in forming thin films onto a wide variety of surfaces. Using dopamine as a model system, catechol analogs will be electrochemically attached, and the resulting thin films analyzed for attachment, thickness, ease of further modification, and morphology. Atomic Force Microscopy (AFM), UV/Visible spectroscopy, soak/stress protocols and microbiology will be used to gauge the success or failure of a thin film plus oligosaccharide combination._x000D_
_x000D_
This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government